Listen to Dr. Jennifer Green and Dr. Neha Pagidipati discuss the utilization of SGLT2i and GLP-1RA in the hospital setting in patients with indications for such therapy, as described in the 2021 ADA Standards of Medical Care and current AHA guidelines, including the recent ASA/AHA Recurrent Stroke prevention guidelines.

Listen to George L. Bakris, MD, FAHA, FASN, Cecilia C. Low Wang, MD, FACP and Neda Rasouli, MD educate clinicians on the updates made in the 2021 ADA Standards of Care related to metformin use and considerations for when the guideline recommends considering use of SGLT-2 Inhibitors and GLP-1 receptor agonists independent of A1C or metformin use.

Listen to Dr. Boris Draznin, an endocrinologist and specialist in diabetes and internal medicine, and Dr. Pam Kushner, a specialist in family medicine discuss how the new American Diabetes Association's 2021 Standards of Care have changed and implications for practice.

Patients with T2D and CKD have a very high risk of CV events. Listen as Dr. Jorge Plutzky and Dr. Neha Pagidipati discuss new therapies to manage cardiovascular and renal risk in patients with T2D. Their discussion is based on new science presented during AHA Scientific Sessions 2020.

Listen as Dr. Eduardo Sanchez from the American Heart Association and Dr. Robert Gabbay from the American Diabetes Association discuss social determinants of health and disparities in health and health care in individuals with type 2 diabetes at risk for cardiovascular disease and COVID-19 and what can be done to improve their outcomes.

Listen to leading experts discuss the new Scientific Statement from the American Heart Association, "Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease," where two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.

Listen to Dr. Jay Shubrook, DO, a primary care physician and Dr. Bankim Bhatt, MD, an adult endocrinologist discuss diabetes management, telemedicine, and lessons learned in the time of COVID-19.

Listen to members of the writing group for the new AHA statement on the clinical management of stable coronary artery disease in patients with T2D. Dr. Suzanne Arnold, Chair, and fellow writing group members, Dr. Prakash Deedwania and Dr. Mikhail Kosiborod will review highlights from the statement, including recent clinical trials which uncovered several new drugs that not only reduce glucose, but also improve cardiovascular and renal outcomes.

People with type 2 diabetes and chronic kidney disease are at three times higher risk of dying from a cardiovascular event. According to the National Kidney Foundation, the two main causes of chronic kidney disease are diabetes and high blood pressure. These two conditions were the primary diagnosis in 75% of kidney failure cases between 2015-2017. Listen to Dr. George Bakris, a nephrologist with expertise in diabetes-related kidney disease, and Dr. Peter McCullough, a cardiologist who is also board certified in internal medicine, discuss how to better screen and manage patients with type 2 diabetes who are at risk for cardiovascular disease and renal disease.

Listen to Dr. Nancy Albert, a clinical nurse specialist and lead researcher in heart failure and Dr. Mikhail Kosiborod, a cardiologist and expert in the fields of diabetes, cardiovascular diseases, cardiometabolic and cardiorenal syndromes, and quality care and outcomes discuss heart failure management in patients with type 2 diabetes and cardiovascular disease.